Seven Action Cream : Itraconazole, Ofloxacin, Ornidazole & Clobetasol Propionate Cream – 30 GM

Icona London Seven Action Cream 30 GM – Itraconazole, Ofloxacin, Ornidazole & Clobetasol Propionate Medicated Topical Cream for Professional Dermatology Skin Care

Icona London Seven Action Cream – 30 GM is a medicated topical dermatology preparation formulated with Itraconazole, Ofloxacin, Ornidazole and Clobetasol Propionate, as identified on the supplied product packaging. The cream is presented with seven care-focused claims: Antifungal, Antibacterial, Anti-Inflammatory, Anti Black Spot, Antiseptic, Anti-Pruritic and Anti-Itch.

The formulation includes Clobetasol Propionate, a highly potent topical corticosteroid. Current drug labeling classifies clobetasol 0.05% formulations as super-high-potency corticosteroids used for the relief of inflammation and itching associated with appropriate corticosteroid-responsive skin conditions. Excessive or prolonged use can increase systemic corticosteroid exposure and the risk of adverse effects, so treatment duration, application area and quantity should follow approved directions.

Itraconazole provides the antifungal element of the ingredient profile. FDA-approved itraconazole products are antifungal medicines used to manage fungal infections, although the approved products cited by U.S. regulators are systemic formulations rather than this specific topical combination. Therefore, the exact topical indication and concentration of itraconazole in Icona London’s formulation must be confirmed from its destination-market authorization.

The product also contains Ofloxacin, a fluoroquinolone antibacterial medicine used against susceptible bacteria in approved formulations. This supports the antibacterial concept displayed on the packaging, but the efficacy, concentration and approved dermatological indication of ofloxacin within this particular combination cream remain To Be Confirmed.

Ornidazole is an antimicrobial agent used internationally for infections involving susceptible anaerobic bacteria and certain protozoa. It is available in some countries but is not approved for marketing by the U.S. FDA, demonstrating why destination-market regulatory verification is particularly important for this formulation.

The 30 GM tube offers a compact format for controlled topical application. The tube and outer retail carton provide clear Icona London branding and prominent Seven Action positioning, making the product easy to identify within regulated dermatology and pharmaceutical ranges.

For B2C users, this cream should not be used simply because a rash, dark mark or irritated area appears to match the packaging claims. Fungal, bacterial and inflammatory conditions can require different treatments, and potent corticosteroids such as clobetasol may mask symptoms when used inappropriately. Use should follow the complete product leaflet and healthcare-professional guidance.

For B2B buyers, Icona London Seven Action Cream may be appropriate for authorized pharmacies, pharmaceutical wholesalers, importers and healthcare distributors, subject to local medicine registration, prescription classification and advertising requirements.

Claims such as Anti Black Spot, Antiseptic, Anti-Pruritic and Anti-Itch should remain limited to the wording authorized for the finished product. They should not be expanded into guaranteed pigmentation removal, permanent cure or universal infection-treatment claims without supporting clinical and regulatory documentation.

Overall, Icona London Seven Action Cream 30 GM provides a multi-ingredient topical dermatology format with antifungal, antibacterial and anti-inflammatory positioning, designed for responsible, medically appropriate skin-care use.